VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMS 2022 | Biomarkers to predict outcomes in patients with myeloma treated with lenalidomide and dexamethasone

Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, comments on the results of a study investigating biomarkers to predict response and resistance to lenalidomide-dexamethasone in elderly patients with multiple myeloma. In this study, patients were randomized to receive lenalidomide and dexamethasone with or without clarithromycin. The study was able to identify immune cell types associated with progression-free survival (PFS) as well as patients at a high risk of infections. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter